This article was originally published here

Curr Pharm Biotechnol. 2021 Sep 6. doi: 10.2174/1389201022666210907115126. Online ahead of print.


Mesenchymal stem cells (MSCs) are multipotent progenitor cells that play crucial roles in the microenvironment of injured tissues. The potential therapeutics of MSCs have attracted extensive attention for several diseases such as acute respiratory distress syndrome (ARDS) and novel coronavirus disease 2019 (COVID-19) pneumonia. MSC-extracellular vesicles have been isolated from MSC-conditioned media (MSC-CM) with similar functional effects as parent MSCs. The therapeutic role of MSCs can be achieved through the balance between the inflammatory and regenerative microenvironments. Clinical settings of MSCs and their extracellular vesicles remain promising for many diseases, such as ARDS and pneumonia. However, their clinical applications remain limited due to the cost of growing and storage facilities of MSCs with a lack of standardized MSC-CM. This review highlights the proposed role of MSCs in pulmonary diseases and discusses the recent advances of MSC application for pneumonia and other lung disorders.

PMID:34493193 | DOI:10.2174/1389201022666210907115126

The rest is here:

Anti-inflammatory Effects of Mesenchymal Stem Cells and Their Secretomes in Pneumonia - DocWire News

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *